Robert J Levy

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/10698454/robert-j-levy-publications-by-year.pdf
Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

177 papers	9,278 citations	49 h-index	92 g-index
184 ext. papers	9,925 ext. citations	7.3 avg, IF	5.64 L-index

#	Paper	IF	Citations
177	Adeno-Associated Viral Vector Immobilization and Local Delivery from Bare Metal Surfaces.. *Methods in Molecular Biology*, **2022**, 2394, 601-616	1.4	
176	Age-related enhanced degeneration of bioprosthetic valves due to leaflet calcification, tissue crosslinking, and structural changes.. *Cardiovascular Research*, **2022**,	9.9	3
175	Robust Chemical Strategy for Stably Labeling Polyester-Based Nanoparticles with BODIPY Fluorophores. *ACS Applied Polymer Materials*, **2022**, 4, 1196-1206	4.3	
174	Stent-based delivery of AAV2 vectors encoding oxidation-resistant apoA1.. *Scientific Reports*, **2022**, 12, 5464	4.9	0
173	Model studies of advanced glycation end product modification of heterograft biomaterials: The effects of in vitro glucose, glyoxal, and serum albumin on collagen structure and mechanical properties. *Acta Biomaterialia*, **2021**, 123, 275-285	10.8	1
172	Altered Responsiveness to TGF and BMP and Increased CD45+ Cell Presence in Mitral Valves Are Unique Features of Ischemic Mitral Regurgitation. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2021**, 41, 2049-2062	9.4	1
171	Noncalcific Mechanisms of Bioprosthetic Structural Valve Degeneration. *Journal of the American Heart Association*, **2021**, 10, e018921	6	10
170	Circulating and tissue matricellular RNA and protein expression in calcific aortic valve disease. *Physiological Genomics*, **2020**, 52, 191-199	3.6	6
169	Experimental Single-Platform Approach to Enhance the Functionalization of Magnetically Targetable Cells. *ACS Applied Bio Materials*, **2020**, 3, 3914-3922	4.1	
168	Stability and bioactivity of pepCD47 attachment on stainless steel surfaces. *Acta Biomaterialia*, **2020**, 104, 231-240	10.8	1
167	Bioprosthetic Heart Valve Calcification: Clinicopathologic Correlations, Mechanisms, and Prevention. *Contemporary Cardiology*, **2020**, 183-215	0.1	1
166	Comparative pathology of human and canine myxomatous mitral valve degeneration: 5HT and TGF- mechanisms. *Cardiovascular Pathology*, **2020**, 46, 107196	3.8	18
165	Pathological Calcification of Biomaterials **2020**, 973-994		3
164	Glycation and Serum Albumin Infiltration Contribute to the Structural Degeneration of Bioprosthetic Heart Valves. *JACC Basic To Translational Science*, **2020**, 5, 755-766	8.7	7
163	Drug-associated valvular heart diseases and serotonin-related pathways: a meta-analysis. *Heart*, **2019**, 105, 1140-1148	5.1	5
162	Serotonin receptor 2B signaling with interstitial cell activation and leaflet remodeling in degenerative mitral regurgitation. *Journal of Molecular and Cellular Cardiology*, **2018**, 115, 94-103	5.8	17
161	Optimizing endothelial cell functionalization for cell therapy of vascular proliferative disease using a direct contact co-culture system. *Drug Delivery and Translational Research*, **2018**, 8, 954-963	6.2	1

160	Porphyrin-Based SOD Mimic MnTnBu OE -2-PyP Inhibits Mechanisms of Aortic Valve Remodeling in Human and Murine Models of Aortic Valve Sclerosis. *Journal of the American Heart Association*, **2018**, 7, e007861	6	11
159	Calcification and Oxidative Modifications Are Associated With Progressive Bioprosthetic Heart Valve Dysfunction. *Journal of the American Heart Association*, **2017**, 6,	6	33
158	Serotonin and catecholamines in the development and progression of heart valve diseases. *Cardiovascular Research*, **2017**, 113, 849-857	9.9	20
157	Paraffin processing of stented arteries using a postfixation dissolution of metallic and polymeric stents. *Cardiovascular Pathology*, **2016**, 25, 483-488	3.8	4
156	The use of CD47-modified biomaterials to mitigate the immune response. *Experimental Biology and Medicine*, **2016**, 241, 1033-41	3.7	17
155	Magnetically enhanced cell delivery for accelerating recovery of the endothelium in injured arteries. *Journal of Controlled Release*, **2016**, 222, 169-75	11.7	22
154	Enhanced biocompatibility of CD47-functionalized vascular stents. *Biomaterials*, **2016**, 87, 82-92	15.6	25
153	The effects of the covalent attachment of 3-(4-hydroxy-3,5-di-tert-butylphenyl) propyl amine to glutaraldehyde pretreated bovine pericardium on structural degeneration, oxidative modification, and calcification of rat subdermal implants. *Journal of Biomedical Materials Research - Part A*, **2015**, 103, 2441-8	5.4	11
152	Nanoparticle delivery of an SN38 conjugate is more effective than irinotecan in a mouse model of neuroblastoma. *Cancer Letters*, **2015**, 360, 205-12	9.9	25
151	Nanoparticle-mediated delivery of a rapidly activatable prodrug of SN-38 for neuroblastoma therapy. *Biomaterials*, **2015**, 51, 22-29	15.6	26
150	Endothelial targeting of nanocarriers loaded with antioxidant enzymes for protection against vascular oxidative stress and inflammation. *Biomaterials*, **2014**, 35, 3708-15	15.6	67
149	Real-time analysis of composite magnetic nanoparticle disassembly in vascular cells and biomimetic media. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 4245-50	11.5	18
148	The susceptibility of bioprosthetic heart valve leaflets to oxidation. *Biomaterials*, **2014**, 35, 2097-102	15.6	29
147	Vascular gene transfer from metallic stent surfaces using adenoviral vectors tethered through hydrolysable cross-linkers. *Journal of Visualized Experiments*, **2014**, e51653	1.6	6
146	The use of the ex vivo Chandler Loop Apparatus to assess the biocompatibility of modified polymeric blood conduits. *Journal of Visualized Experiments*, **2014**,	1.6	4
145	Stent-mediated gene delivery for site-specific transgene administration to the airway epithelium and management of tracheobronchial tumors. *Respiration*, **2014**, 88, 406-17	3.7	6
144	Addressing the Inflammatory Response to Clinically Relevant Polymers by Manipulating the Host Response Using ITIM Domain-Containing Receptors. *Polymers*, **2014**, 6, 2526-2551	4.5	14
143	Pathological Calcification of Biomaterials **2013**, 739-754		3

142	Site-specific gene delivery to stented arteries using magnetically guided zinc oleate-based nanoparticles loaded with adenoviral vectors. *FASEB Journal*, **2013**, 27, 2198-206	0.9	29
141	Intracellular signaling mechanisms associated with CD47 modified surfaces. *Biomaterials*, **2013**, 34, 8640-8	15.6	14
140	Modulation of NO and ROS production by AdiNOS transduced vascular cells through supplementation with L-Arg and BH4: implications for gene therapy of restenosis. *Atherosclerosis*, **2013**, 230, 23-32	3.1	15
139	Adenoviral vector tethering to metal surfaces via hydrolyzable cross-linkers for the modulation of vector release and transduction. *Biomaterials*, **2013**, 34, 6938-48	15.6	10
138	Endovascular Gene Delivery from a Stent Platform: Gene- Eluting Stents. *Angiology: Open Access*, **2013**, 1,		4
137	Anchoring of self-assembled plasmid DNA/anti-DNA antibody/cationic lipid micelles on bisphosphonate-modified stent for cardiovascular gene delivery. *International Journal of Nanomedicine*, **2013**, 8, 1029-35	7.3	5
136	Diminished adhesion and activation of platelets and neutrophils with CD47 functionalized blood contacting surfaces. *Biomaterials*, **2012**, 33, 5803-11	15.6	37
135	Site Specific Controlled Release for Cardiovascular Disease: Translational Directions **2012**, 445-492		1
134	Formulation and in vitro characterization of composite biodegradable magnetic nanoparticles for magnetically guided cell delivery. *Pharmaceutical Research*, **2012**, 29, 1232-41	4.5	20
133	Aortic valve cyclic stretch causes increased remodeling activity and enhanced serotonin receptor responsiveness. *Annals of Thoracic Surgery*, **2011**, 92, 147-53	2.7	39
132	Triglycidyl amine crosslinking combined with ethanol inhibits bioprosthetic heart valve calcification. *Annals of Thoracic Surgery*, **2011**, 92, 858-65	2.7	19
131	The effect of CD47 modified polymer surfaces on inflammatory cell attachment and activation. *Biomaterials*, **2011**, 32, 4317-26	15.6	58
130	Targeting stents with local delivery of paclitaxel-loaded magnetic nanoparticles using uniform fields. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 8346-51	11.5	158
129	Biomechanical and biologic effects of meniscus stabilization using triglycidyl amine. *Journal of Biomedical Materials Research - Part A*, **2010**, 93, 235-42	5.4	3
128	Endothelial delivery of antioxidant enzymes loaded into non-polymeric magnetic nanoparticles. *Journal of Controlled Release*, **2010**, 146, 144-51	11.7	91
127	Prevention of polyurethane oxidative degradation with phenolic antioxidants covalently attached to the hard segments: structure-function relationships. *Journal of Biomedical Materials Research - Part A*, **2010**, 94, 751-9	5.4	6
126	CD47-dependent molecular mechanisms of blood outgrowth endothelial cell attachment on cholesterol-modified polyurethane. *Biomaterials*, **2010**, 31, 6394-9	15.6	9
125	Site-specific gene therapy for cardiovascular disease. *Current Opinion in Drug Discovery & Development*, **2010**, 13, 203-13		10

124	Magnetically responsive biodegradable nanoparticles enhance adenoviral gene transfer in cultured smooth muscle and endothelial cells. *Molecular Pharmaceutics*, **2009**, 6, 1380-7	5.6	32
123	Fenfluramine disrupts the mitral valve interstitial cell response to serotonin. *American Journal of Pathology*, **2009**, 175, 988-97	5.8	39
122	Local delivery of gene vectors from bare-metal stents by use of a biodegradable synthetic complex inhibits in-stent restenosis in rat carotid arteries. *Circulation*, **2008**, 117, 2096-103	16.7	60
121	High field gradient targeting of magnetic nanoparticle-loaded endothelial cells to the surfaces of steel stents. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 698-703	11.5	213
120	Immobilization of plasmid DNA on an anti-DNA antibody modified coronary stent for intravascular site-specific gene therapy. *Journal of Gene Medicine*, **2008**, 10, 421-9	3.5	27
119	Biological stability of polyurethane modified with covalent attachment of di-tert-butyl-phenol. *Journal of Biomedical Materials Research - Part A*, **2007**, 82, 1004-11	5.4	12
118	In vivo biomechanical assessment of triglycidylamine crosslinked pericardium. *Biomaterials*, **2007**, 28, 5390-8	15.6	18
117	Mechanisms of the in vivo inhibition of calcification of bioprosthetic porcine aortic valve cusps and aortic wall with triglycidylamine/mercapto bisphosphonate. *Biomaterials*, **2007**, 28, 690-9	15.6	41
116	Magnetically driven plasmid DNA delivery with biodegradable polymeric nanoparticles. *FASEB Journal*, **2007**, 21, 2510-9	0.9	104
115	Transforming growth factor-beta1 mechanisms in aortic valve calcification: increased alkaline phosphatase and related events. *Annals of Thoracic Surgery*, **2007**, 83, 946-53	2.7	120
114	Prevention of oxidative degradation of polyurethane by covalent attachment of di-tert-butylphenol residues. *Journal of Biomedical Materials Research - Part A*, **2006**, 78, 653-61	5.4	17
113	Serotonin transporter mechanisms and cardiac disease. *Circulation*, **2006**, 113, 2-4	16.7	28
112	Bisphosphonate-mediated gene vector delivery from the metal surfaces of stents. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 159-64	11.5	85
111	Adenoviral gene vector tethering to nanoparticle surfaces results in receptor-independent cell entry and increased transgene expression. *Molecular Therapy*, **2006**, 14, 382-91	11.7	26
110	Cholesterol-modified polyurethane valve cusps demonstrate blood outgrowth endothelial cell adhesion post-seeding in vitro and in vivo. *Annals of Thoracic Surgery*, **2006**, 81, 47-55	2.7	31
109	In-vivo dynamic deformation of the mitral valve anterior leaflet. *Annals of Thoracic Surgery*, **2006**, 82, 1369-77	2.7	111
108	Triglycidylamine crosslinking of porcine aortic valve cusps or bovine pericardium results in improved biocompatibility, biomechanics, and calcification resistance: chemical and biological mechanisms. *American Journal of Pathology*, **2005**, 166, 1-13	5.8	65
107	Calcification of tissue heart valve substitutes: progress toward understanding and prevention. *Annals of Thoracic Surgery*, **2005**, 79, 1072-80	2.7	509

106	Prevention of calcification of bioprosthetic heart valve cusp and aortic wall with ethanol and aluminum chloride. *Annals of Thoracic Surgery*, **2005**, 79, 897-904	2.7	16
105	A novel mercapto-bisphosphonate as an efficient anticalcification agent for bioprosthetic tissues. *Journal of Organometallic Chemistry*, **2005**, 690, 2543-2547	2.3	32
104	Site specific gene delivery in the cardiovascular system. *Journal of Controlled Release*, **2005**, 109, 37-48	11.7	31
103	Cholesterol-derivatized polyurethane: characterization and endothelial cell adhesion. *Journal of Biomedical Materials Research - Part A*, **2005**, 72, 200-12	5.4	25
102	Posttranslational control of a cardiac ion channel transgene in vivo: clarithromycin-hMiRP1-Q9E interactions. *Human Gene Therapy*, **2005**, 16, 906-10	4.8	22
101	Posttranslational Control of a Cardiac Ion Channel Transgene In Vivo: Clarithromycin-hMiRP1-Q9E Interactions. *Human Gene Therapy*, **2005**, 050701034702007	4.8	
100	Delivery and expression of pDNA embedded in collagen matrices. *Journal of Controlled Release*, **2004**, 95, 309-20	11.7	71
99	Ethanol inhibition of porcine bioprosthetic heart valve cusp calcification is enhanced by reduction with sodium borohydride. *Journal of Heart Valve Disease*, **2004**, 13, 487-93		13
98	Polymer degradation and in vitro release of a model protein from poly(D,L-lactide-co-glycolide) nano- and microparticles. *Journal of Controlled Release*, **2003**, 92, 173-87	11.7	398
97	Prevention of polyurethane valve cusp calcification with covalently attached bisphosphonate diethylamino moieties. *Journal of Biomedical Materials Research Part B*, **2003**, 66, 385-95		35
96	Progression of aortic valve stenosis: TGF-beta1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis. *Annals of Thoracic Surgery*, **2003**, 75, 457-65; discussion 465-6	2.7	338
95	Calcification resistance with aluminum-ethanol treated porcine aortic valve bioprostheses in juvenile sheep. *Annals of Thoracic Surgery*, **2003**, 75, 1267-73	2.7	23
94	The incorporation of an ion channel gene mutation associated with the long QT syndrome (Q9E-hMiRP1) in a plasmid vector for site-specific arrhythmia gene therapy: in vitro and in vivo feasibility studies. *Human Gene Therapy*, **2003**, 14, 907-22	4.8	26
93	Inhibition of cusp and aortic wall calcification in ethanol- and aluminum-treated bioprosthetic heart valves in sheep: background, mechanisms, and synergism. *Journal of Heart Valve Disease*, **2003**, 12, 209-16; discussion 216		33
92	Endovascular microcoil gene delivery using immobilized anti-adenovirus antibody for vector tethering. *Stroke*, **2002**, 33, 1376-82	6.7	38
91	Serotonin mechanisms in heart valve disease I: serotonin-induced up-regulation of transforming growth factor-beta1 via G-protein signal transduction in aortic valve interstitial cells. *American Journal of Pathology*, **2002**, 161, 2111-21	5.8	154
90	Serotonin mechanisms in heart valve disease II: the 5-HT2 receptor and its signaling pathway in aortic valve interstitial cells. *American Journal of Pathology*, **2002**, 161, 2209-18	5.8	97
89	Gene delivery to pig coronary arteries from stents carrying antibody-tethered adenovirus. *Human Gene Therapy*, **2002**, 13, 443-54	4.8	87

88	Thymosin beta4 regulation, expression and function in aortic valve interstitial cells. *Journal of Heart Valve Disease*, **2002**, 11, 726-35		12
87	High reactivity of alkyl sulfides towards epoxides under conditions of collagen fixation--a convenient approach to 2-amino-4-butyrolactones. *Biomaterials*, **2001**, 22, 2501-6	15.6	14
86	Elastomeric polyurethanes modified with geminal bisphosphonate groups. *Journal of Polymer Science Part A*, **2001**, 39, 105-116	2.5	20
85	Matrix metalloproteinase-2 is associated with tenascin-C in calcific aortic stenosis. *American Journal of Pathology*, **2001**, 159, 321-7	5.8	141
84	Gene delivery from a DNA controlled-release stent in porcine coronary arteries. *Nature Biotechnology*, **2000**, 18, 1181-4	44.5	204
83	Inhibition of matrix metalloproteinase activity attenuates tenascin-C production and calcification of implanted purified elastin in rats. *American Journal of Pathology*, **2000**, 157, 885-93	5.8	69
82	Gene transfection using biodegradable nanospheres: results in tissue culture and a rat osteotomy model. *Colloids and Surfaces B: Biointerfaces*, **1999**, 16, 281-290	6	54
81	Mechanisms of bioprosthetic heart valve failure: fatigue causes collagen denaturation and glycosaminoglycan loss. *Journal of Biomedical Materials Research Part B*, **1999**, 46, 44-50		110
80	Founders Award, 25th Annual Meeting of the Society for Biomaterials, perspectives. Providence, RI, April 28-May 2, 1999. Tissue heart valves: current challenges and future research perspectives. *Journal of Biomedical Materials Research Part B*, **1999**, 47, 439-65		334
79	Elastin calcification and its prevention with aluminum chloride pretreatment. *American Journal of Pathology*, **1999**, 155, 973-82	5.8	83
78	Tissue heart valves: Current challenges and future research perspectives **1999**, 47, 439		41
77	A DNA controlled-release coating for gene transfer: transfection in skeletal and cardiac muscle. *Journal of Pharmaceutical Sciences*, **1998**, 87, 1347-50	3.9	67
76	Arterial uptake of biodegradable nanoparticles: effect of surface modifications. *Journal of Pharmaceutical Sciences*, **1998**, 87, 1229-34	3.9	142
75	Gene therapy for tissue repair and regeneration. *Advanced Drug Delivery Reviews*, **1998**, 33, 53-69	18.5	79
74	Arterial uptake of biodegradable nanoparticles for intravascular local drug delivery: results with an acute dog model. *Journal of Controlled Release*, **1998**, 54, 201-11	11.7	111
73	Prevention of calcification of glutaraldehyde-crosslinked porcine aortic cusps by ethanol preincubation: mechanistic studies of protein structure and water-biomaterial relationships. *Journal of Biomedical Materials Research Part B*, **1998**, 40, 577-85		53
72	Inhibition of aortic wall calcification in bioprosthetic heart valves by ethanol pretreatment: biochemical and biophysical mechanisms. *Journal of Biomedical Materials Research Part B*, **1998**, 42, 30-7		48
71	Prevention of acute inducible atrial flutter in dogs by using an ibutilide-polymer-coated pacing electrode. *Journal of Cardiovascular Pharmacology*, **1998**, 31, 449-55	3.1	6

70	Prevention of calcification of glutaraldehyde-crosslinked porcine aortic cusps by ethanol preincubation: Mechanistic studies of protein structure and waterBiomaterial relationships **1998**, 40, 577		2
69	Prevention of bioprosthetic heart valve calcification by ethanol preincubation. Efficacy and mechanisms. *Circulation*, **1997**, 95, 479-88	16.7	182
68	Capillary electrophoresis of supercoiled and linear DNA in dilute hydroxyethyl cellulose solution. *Analytical Chemistry*, **1997**, 69, 1192-6	7.8	33
67	Current Progress in Anticalcif ication for Bioprosthetic and Polymeric Heart Valves. *Cardiovascular Pathology*, **1997**, 6, 219-29	3.8	36
66	Refinement of the alpha aminooleic acid bioprosthetic valve anticalcification technique. *Annals of Thoracic Surgery*, **1997**, 64, 50-8	2.7	27
65	Nanoparticle drug delivery system for restenosis. *Advanced Drug Delivery Reviews*, **1997**, 24, 63-85	18.5	126
64	The effect of intramural delivery of polymeric nanoparticles loaded with the antiproliferative 2-aminochromone U-86983 on neointimal hyperplasia development in balloon-injured porcine coronary arteries. *Advanced Drug Delivery Reviews*, **1997**, 24, 87-108	18.5	20
63	Gene-based therapies for restenosis. *Advanced Drug Delivery Reviews*, **1997**, 24, 109-120	18.5	12
62	The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. *Pharmaceutical Research*, **1997**, 14, 1568-73	4.5	655
61	Differential calcification of cusps and aortic wall of failed stented porcine bioprosthetic valves. *Journal of Biomedical Materials Research Part B*, **1997**, 34, 411-5		17
60	Synergistic inhibition of calcification of porcine aortic root with preincubation in FeCl3 and alpha-amino oleic acid in a rat subdermal model. *Journal of Biomedical Materials Research Part B*, **1997**, 38, 43-8		8
59	Sustained-release local hirulog therapy decreases early thrombosis but not neointimal thickening after arterial stenting. *American Heart Journal*, **1996**, 131, 211-8	4.9	13
58	Controlled release implant dosage forms for cardiac arrhythmias: Review and perspectives. *Drug Delivery*, **1996**, 3, 137-42	7	9
57	Gastrointestinal uptake of biodegradable microparticles: effect of particle size. *Pharmaceutical Research*, **1996**, 13, 1838-45	4.5	703
56	Calcification of polyurethanes implanted subdermally in rats is enhanced by calciphylaxis. *Journal of Biomedical Materials Research Part B*, **1996**, 31, 201-7		20
55	Degradation of Materials in the Biological Environment **1996**, 411-453		1
54	Controlled-Release Drug Matrices for Local Immunosuppression of Organ Transplants. *Medical Intelligence Unit*, **1996**, 161-168		
53	Polymeric drug delivery systems for treatment of cardiovascular calcification, arrhythmias and restenosis. *Journal of Controlled Release*, **1995**, 36, 137-147	11.7	7

52	Model features of a cardiac iontophoretic drug delivery implant. *Pharmaceutical Research*, **1995**, 12, 790-5	4.5	7
51	Novel delivery of antiarrhythmic agents. *Clinical Pharmacokinetics*, **1995**, 29, 1-5	6.2	5
50	Calcification of valved aortic allografts in rats: effects of age, crosslinking, and inhibitors. *Journal of Biomedical Materials Research Part B*, **1995**, 29, 217-26		25
49	Effects of antisense c-myb oligonucleotides on vascular smooth muscle cell proliferation and response to vessel wall injury. *Circulation Research*, **1995**, 76, 505-13	15.7	93
48	Onset and progression of calcification in porcine aortic bioprosthetic valves Implanted as orthotopic mitral valve replacements in juvenile sheep. *Journal of Thoracic and Cardiovascular Surgery*, **1994**, 108, 880-887	1.5	67
47	Sotalol controlled-release systems for arrhythmias: in vitro characterization, in vivo drug disposition, and electrophysiologic effects. *Journal of Pharmaceutical Sciences*, **1994**, 83, 156-64	3.9	23
46	Modulated drug release using iontophoresis through heterogeneous cation-exchange membranes. 2. Influence of cation-exchanger content on membrane resistance and characteristic times. *Journal of Pharmaceutical Sciences*, **1994**, 83, 1482-94	3.9	8
45	Phosphonated polyurethanes that resist calcification. *Journal of Applied Biomaterials: an Official Journal of the Society for Biomaterials*, **1994**, 5, 65-77		21
44	Effect of 2-amino oleic acid exposure conditions on the inhibition of calcification of glutaraldehyde cross-linked porcine aortic valves. *Journal of Biomedical Materials Research Part B*, **1994**, 28, 1485-95		42
43	Pathology of substitute heart valves: new concepts and developments. *Journal of Cardiac Surgery*, **1994**, 9, 222-7	1.3	63
42	Site-specific dexamethasone delivery for the prevention of neointimal thickening after vascular stent implantation. *Coronary Artery Disease*, **1994**, 5, 435-42	1.4	29
41	Epicardial administration of ibutilide from polyurethane matrices: effects on defibrillation threshold and electrophysiologic parameters. *Journal of Cardiovascular Pharmacology*, **1994**, 24, 826-40	3.1	39
40	Strategies for Treating Arterial Restenosis Using Polymeric Controlled Release Implants **1994**, 259-268		
39	Determinants of the modulated release of antiarrhythmic drugs by iontophoresis through polymer membranes. *Macromolecules*, **1993**, 26, 2264-2272	5.5	13
38	Inhibition of calcification of glutaraldehyde pretreated porcine aortic valve cusps with sodium dodecyl sulfate: preincubation and controlled release studies. *Journal of Biomedical Materials Research Part B*, **1993**, 27, 1477-84		47
37	Effects of metallic ions and diphosphonates on inhibition of pericardial bioprosthetic tissue calcification and associated alkaline phosphatase activity. *Biomaterials*, **1993**, 14, 371-7	15.6	22
36	Synergistic inhibition of the calcification of glutaraldehyde pretreated bovine pericardium in a rat subdermal model by FeCl3 and ethanehydroxydiphosphonate: preincubation and polymeric controlled release studies. *Biomaterials*, **1993**, 14, 705-11	15.6	16
35	The efficacy of controlled release D-sotalol-polyurethane epicardial implants for ventricular arrhythmias due to acute ischemia in dogs. *Journal of Controlled Release*, **1993**, 23, 75-85	11.7	10

34	Pathological considerations in replacement cardiac valves. *Cardiovascular Pathology*, **1992**, 1, 29-52	3.8	106
33	Modulated drug release using iontophoresis through heterogeneous cation exchange membranes: membrane preparation and influence of resin crosslinkage. *Macromolecules*, **1992**, 25, 2531-2540	5.5	20
32	Antimineralization treatments for bioprosthetic heart valves. *Journal of Thoracic and Cardiovascular Surgery*, **1992**, 104, 1285-1288	1.5	58
31	Local release polymeric-controlled immunotherapy of cardiac transplants in rats. *Polymers for Advanced Technologies*, **1992**, 3, 345-350	3.2	3
30	Cardiovascular implant calcification: a survey and update. *Biomaterials*, **1991**, 12, 707-14	15.6	63
29	Initiation of mineralization in bioprosthetic heart valves: studies of alkaline phosphatase activity and its inhibition by AlCl3 or FeCl3 preincubations. *Journal of Biomedical Materials Research Part B*, **1991**, 25, 905-35		68
28	Polymeric Controlled Release of Cardiovascular Drugs **1991**, 231-238		2
27	Efficacy of epicardial controlled-release lidocaine for ventricular tachycardia induced by rapid ventricular pacing in dogs. *Journal of Cardiovascular Pharmacology*, **1990**, 16, 812-7	3.1	10
26	Conversion of ouabain-induced ventricular tachycardia in dogs with epicardial lidocaine: pharmacodynamics and functional effects. *Pharmaceutical Research*, **1990**, 7, 28-33	4.5	8
25	Prevention of calcification of glutaraldehyde pretreated bovine pericardium through controlled release polymeric implants: studies of Fe3+, Al3+, protamine sulphate and levamisole. *Biomaterials*, **1990**, 11, 718-23	15.6	39
24	Controlled release implants for cardiovascular disease. *Journal of Controlled Release*, **1990**, 11, 245-254	11.7	17
23	Sustained behavioral recovery from unilateral nigrostriatal damage produced by the controlled release of dopamine from a silicone polymer pellet placed into the denervated striatum. *Brain Research*, **1990**, 508, 60-4	3.7	53
22	Covalent binding of aminopropanehydroxydiphosphonate to glutaraldehyde residues in pericardial bioprosthetic tissue: stability and calcification inhibition studies. *Experimental and Molecular Pathology*, **1989**, 50, 291-302	4.4	29
21	Prevention of calcification of bioprosthetic heart valve leaflets by Ca2+ diphosphonate pretreatment. *Journal of Pharmaceutical Sciences*, **1988**, 77, 740-4	3.9	19
20	Retardation of calcification of bovine pericardium used in bioprosthetic heart valves by phosphocitrate and a synthetic analogue. *Biomaterials*, **1988**, 9, 393-7	15.6	18
19	Cardiac controlled release for arrhythmia therapy: Lidocaine-polyurethane matrix studies. *Journal of Controlled Release*, **1988**, 8, 157-165	11.7	20
18	Inhibition of bioprosthetic heart valve calcification with aminodiphosphonate covalently bound to residual aldehyde groups. *Annals of Thoracic Surgery*, **1988**, 46, 309-16	2.7	47
17	Prevention of leaflet calcification of bioprosthetic heart valves with diphosphonate injection therapy. *Journal of Thoracic and Cardiovascular Surgery*, **1987**, 94, 551-557	1.5	47

16	Controlled-release drug delivery of diphosphonates to inhibit bioprosthetic heart valve calcification: release rate modulation with silicone matrices via drug solubility and membrane coating. *Journal of Pharmaceutical Sciences*, **1987**, 76, 271-6	3.9	63
15	Inhibition of bioprosthetic heart valve calcification by sustained local delivery of Ca and Na diphosphonate via controlled release matrices. *ASAIO Transactions*, **1986**, 32, 587-90		14
14	Controlled release of diphosphonate to inhibit bioprosthetic heart valve calcification: Dose-response and mechanistic studies. *Journal of Controlled Release*, **1986**, 4, 181-194	11.7	47
13	Biomaterials-Associated Pathology of Cardiac Valve Prostheses: Clinical Explant Analysis and Studies of Tissue Valve Calcification. *Materials Research Society Symposia Proceedings*, **1985**, 55, 29		
12	Calcification of Cardiac Valve Bioprostheses **1985**, 661-668		5
11	Bioprosthetic Heart Valve Failure: Pathology and Pathogenesis. *Cardiology Clinics*, **1984**, 2, 717-739	2.5	89
10	Porcine bioprosthetic valve calcification in bovine left ventricle-aorta shunts: studies of the deposition of vitamin K-dependent proteins. *Annals of Thoracic Surgery*, **1983**, 36, 187-92	2.7	35
9	Mechanism of calcification of porcine bioprosthetic aortic valve cusps: role of T-lymphocytes. *American Journal of Cardiology*, **1983**, 52, 629-31	3	68
8	Calcification of cardiac valve bioprostheses. *Journal of Thoracic and Cardiovascular Surgery*, **1982**, 83, 602-609	1.5	80
7	Use of Hancock porcine xenografts in children and adolescents. *American Journal of Cardiology*, **1980**, 46, 429-38	3	139
6	Vitamin K-dependent calcium binding proteins in aortic valve calcification. *Journal of Clinical Investigation*, **1980**, 65, 563-6	15.9	57
5	Atherocalcin, a gamma-carboxyglutamic acid containing protein from atherosclerotic plaque. *Biochemical and Biophysical Research Communications*, **1979**, 91, 41-9	3.4	78
4	gamma-Carboxyglutamate excretion and warfarin therapy. *Clinical Pharmacology and Therapeutics*, **1979**, 25, 562-70	6.1	28
3	Growth after surgical repair of simple D-transposition of the great arteries. *Annals of Thoracic Surgery*, **1978**, 25, 225-30	2.7	25
2	Birthweight of infants with congenital heart disease. *JAMA Pediatrics*, **1978**, 132, 249-54		10
1	Glycation and Serum Albumin Infiltration Contribute to the Structural Degeneration of Bioprosthetic Heart Valves		2